Actively Recruiting
Evaluating the Galleri Multi-Cancer Early Detection Test in Medicare Adults Aged 50 and Older A Multi-Center Prospective Cohort Study Comparing Galleri Plus Usual Care Versus Usual Care Alone
Led by GRAIL, Inc. · Updated on 2026-10-19
50000
Participants Needed
72
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the real-world impact, including safety and test accuracy, of the Galleri4 multi-cancer early detection blood test in Medicare beneficiaries aged 50 years and older. This multi-center prospective cohort study aims to represent the Medicare population and compares usual care with and without the addition of the Galleri test. The study focuses on screening for cancer and assessing how the test affects cancer diagnosis and management over time. Participants are grouped into two arms one receiving the Galleri test alongside usual care, and a second group receiving usual care alone without the Galleri test. The Galleri test involves blood collection and multi-cancer early detection testing with results returned to participants. The study is non-randomized and runs parallel for both groups, observing outcomes over up to three years. During the study, participants are monitored for the incidence of late-stage stage IV cancers. Researchers also track safety by counting invasive procedures prompted by test results, adherence to recommended cancer screenings, and healthcare resources used for cancer diagnostics. The total study duration includes up to three years of follow-up to observe outcomes, with no masking or blinding involved.
CONDITIONS
Brief Title
Galleri® in the Medicare Population.
Research Team
G
GRAIL Medical Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here